Viking Therapeutics (NASDAQ: VKTX) announced that it has initiated the clinical development program for VK5211, the company’s lead program for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE